What happens when solubility data arrives late?
By the time solubility and aggregation data arrives, your shortlist is already set — and often already wrong.
Hit triage looks like a solved problem. You screen a library, rank by potency and selectivity, and promote the top compounds. Somewhere downstream — often after significant chemistry investment — solubility and aggregation catch up with the shortlist. Some of the hits you promoted don’t survive. Some of the ones you dropped might have.
This is the order almost every discovery pipeline runs on. It’s also why so many compounds die later in development for reasons that were visible much earlier — just not measurable at the speed or cost that triage allows.
The decision that gets made with half the evidence
When you rank hits by potency alone, you’re making a decision with half the evidence. A potent compound that aggregates will give you false SAR. A potent compound that won’t dissolve at working concentrations is already failing — you just can’t see it yet. By the time pre-formulation catches the problem, the chemistry is already in flight and the opportunity cost is real.
Teams have known this for years. The problem has always been measurement economics. Clean solubility and aggregation data across a hit list has meant HPLC, milligram-scale compound, and days of work per series. That math doesn’t fit triage. So the physical-property data gets pushed downstream — and the shortlist goes out without it.
The cost of catching it late
The downstream cost of a late solubility flag is larger than it looks. Chemists optimise around a lead that won’t formulate. Biologists generate SAR on aggregating compounds and get data they can’t trust. Formulation teams inherit an intractable problem and burn months on salt screens, polymorphs, or excipient panels that were never going to work.
Every one of those steps costs money, burns scarce compound, and delays the next decision. A clean triage isn’t just fewer headaches — it’s real ROI: less wasted chemistry, less wasted formulation work, fewer programmes stalled on problems that were knowable months earlier.
What changes when physics lands at triage
If solubility and aggregation data arrives before the shortlist is set, the shortlist is different. Discovery stops promoting compounds that won’t survive formulation. Pre-formulation stops inheriting problems that should have been caught upstream. The list is shorter, cleaner, and more predictive of what actually makes it to the next stage.
That’s the shift ORYL F1 was built for — a plate-based, low-compound profiling instrument that puts solubility and aggregation into the triage window, not after it. 384 wells in ~15 minutes. ~100× less compound than HPLC-based methods. Decision-ready data while you’re still triaging, not months after.
Replace late surprises with early certainty.